Aberdeen Group plc Purchases 72,770 Shares of Dyne Therapeutics, Inc. $DYN

Aberdeen Group plc raised its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 15.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 556,733 shares of the company’s stock after buying an additional 72,770 shares during the quarter. Aberdeen Group plc owned about 0.39% of Dyne Therapeutics worth $7,043,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of DYN. Darwin Wealth Management LLC grew its holdings in shares of Dyne Therapeutics by 0.5% in the third quarter. Darwin Wealth Management LLC now owns 173,517 shares of the company’s stock valued at $2,195,000 after purchasing an additional 861 shares in the last quarter. Ameritas Investment Partners Inc. lifted its position in Dyne Therapeutics by 11.1% during the second quarter. Ameritas Investment Partners Inc. now owns 9,582 shares of the company’s stock valued at $91,000 after purchasing an additional 955 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Dyne Therapeutics by 25.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock worth $70,000 after buying an additional 1,109 shares in the last quarter. Caxton Associates LLP increased its holdings in shares of Dyne Therapeutics by 10.9% in the 2nd quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock worth $158,000 after buying an additional 1,627 shares during the last quarter. Finally, CWM LLC raised its position in shares of Dyne Therapeutics by 168.1% during the 2nd quarter. CWM LLC now owns 3,030 shares of the company’s stock valued at $29,000 after buying an additional 1,900 shares in the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Stock Down 2.4%

NASDAQ:DYN opened at $14.88 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.47 and a quick ratio of 13.47. The firm has a market cap of $2.13 billion, a PE ratio of -4.07 and a beta of 1.30. The company has a 50-day moving average of $17.92 and a 200 day moving average of $16.78. Dyne Therapeutics, Inc. has a 1-year low of $6.36 and a 1-year high of $25.00.

Analysts Set New Price Targets

DYN has been the subject of several recent research reports. Chardan Capital reiterated a “buy” rating and issued a $38.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, December 9th. HC Wainwright lifted their target price on Dyne Therapeutics from $46.00 to $60.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Wall Street Zen lowered Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, December 28th. Sanford C. Bernstein set a $23.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, December 9th. Finally, Stifel Nicolaus increased their target price on shares of Dyne Therapeutics from $36.00 to $39.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Dyne Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $38.41.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.